Navigation Links
Telik Announces Financial Results For 2008 Second Quarter
Date:8/11/2008

idates or any product that Telik may develop, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize its product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

Telik, Inc.

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Operating costs and expenses:

Research and development $8,236 $11,869 16,431 $24,813

General and administrative 2,773 3,979 5,186 7,631

Restructuring costs - (33) - 1,356

Total operating costs and

expenses 11,009 15,815 21,617 33,800

Loss from operations (11,009) (15,815) (21,617) (33,800)

Interest and other income

(expense), net (2,560) 1,492 (1,760) 3,155

Net loss
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
2. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
3. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
4. Telik Announces First Quarter 2008 Financial Results
5. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
6. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
7. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
8. Telik Announces Year-End Financial Release, Conference Call and Webcast
9. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
10. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
11. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... be the liaison between United States plasma and fusion science ... of ITER , an international fusion experiment that eventually ... source. , ,On May 24, the seven international ITER participants ... Department of Energy and its ITER Project Office ...
... Madison, Wis. - The parent company of a ... the voluntary nature of the product following the signing ... from requiring them to be implanted. , ,Scott Silverman, ... VeriChip Corp., said the company's practices are consistent with ...
... MINNEAPOLIS - I recently interviewed Robert M. Price about ... Managing the Creative Enterprise". This column includes his comments ... , ,"At its most basic level," he writes, "business ... people orientation is evident as he led Control Data ...
Cached Biology Technology:UW-Madison professor to coordinate U.S. fusion science effort 2Company defends RFID implant product 2New book from former CDC CEO walks readers through innovation 2New book from former CDC CEO walks readers through innovation 3New book from former CDC CEO walks readers through innovation 4
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... In an advance toward solving a 50-year-old mystery, scientists ... drinking water, toothpastes, mouth rinses and other oral-care products ... journal Langumir . Karin Jacobs and colleagues ... still exists over exactly how fluoride compounds reduce the ...
... 2013   Exemplar LIMS™  has been selected as the lab ... Sinai Medical Center in New York . ... (NGS) platform workflows from request through secondary analysis. ... laboratory, and Exemplar LIMS is used to perform the detailed ...
... ends while their leaves are more pointed? In a new ... PLOS Biology , scientists from the John Innes Centre and ... petals is controlled by a hidden map located within the ... functions related to their shape. Leaves acquire sugars for a ...
Cached Biology News:Mount Sinai Selects Exemplar LIMS for Genomics Core Facility 2How petals get their shape 2
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Time- and temperature-controlled microwave ... Rehydration and Antigen Retrieval of ... offers ease of use, high ... and high performance. When used ...
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
Biology Products: